A Phase 3 interventional study of Combination Product: AURN001 + Y-27632 and Placebo in Corneal Edema, Corneal Endothelial Dysfunction and Fuchs Endothelial Corneal Dysfunction, sponsored by Aurion Biotech. Active, not recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Aurion Biotech · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Corneal Edema with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Corneal Edema · United States.
Among the 17 studies in Corneal Edema with a site in United States, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 3, and was the 16th registered.
39 studies on the registry are indexed under Corneal Edema; 8 are open to participants now.
Browse Corneal Edema studies →2 of the 17 studies in Corneal Edema with a site in United States are open now. Recruiting first, the newest first:
Emmecell · Sites in United States
Ages 21+
University of Miami · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Corneal Edema studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 5
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 52 across 31 interventional studies indexed under Corneal Edema.
Median enrollment 61 across the 14 interventional studies, 55 across the 3 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
Aurion Biotech is the lead sponsor of 4 studies on the registry; none are open to participants now.
Aurion Biotech has 4 studies filed under Corneal Edema — fewer than ten, so there is no comparison to draw.
3 of the studies in Corneal Edema with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07368959Phase 3Aurion BiotechAURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction | 2027-06 |
| NCT07729137EmmecellStudy of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction | 2027-08 |
| NCT06261346University of MiamiPlasma Rich in Growth Factors in Corneal Endothelial Transplantation | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Corneal Edema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of single injection dose of AURN001 compared with placebo in adult participants with corneal edema secondary to corneal endothelial dysfunction.
Key Ocular Inclusion Criteria:
(All ocular criteria apply to the study eye unless noted otherwise)
Key Ocular Exclusion Criteria:
(All ocular criteria apply to the study eye unless noted otherwise)
Other inclusion/exclusion criteria may apply.
Participants will receive single dose of AURN001
Drug: Combination Product: AURN001 + Y-27632
Participants will receive single dose of placebo control.
Other: Placebo
AURN001 will be injected to the anterior chamber of the eye.
Placebo control will be injected to the anterior chamber of the eye.
Percentage of participants who achieve a ≥ 15-letter improvement (3-line gain) from baseline in Best Corrected Visual Acuity (BCVA) at Month 6
Time frame: At Month 6
Change from baseline in non-contact Central Corneal Thickness (CCT) at Month 6
Time frame: Baseline (Day 1) and At Month 6
Change from baseline in BCVA at Month 6
Time frame: Baseline (Day 1) and At Month 6
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aurion Biotech